DexCom, Inc. (DXCM)
Healthcare • Medical Devices
StockNasdaqGSUnited StatesUS2521311074
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by DexCom, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:38. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 16:00 | 0.72 | — | — | Upcoming |
| 29 Oct 2026 16:00 | 0.67 | 0.73 | +8.3% | Beat |
| 30 Jul 2026 16:00 | 0.61 | 0.70 | +15.1% | Beat |
| 30 Apr 2026 16:00 | 0.47 | 0.56 | +19.0% | Beat |
| 12 Feb 2026 16:00 | 0.65 | 0.68 | +4.5% | Beat |
| 30 Oct 2025 16:00 | 0.57 | 0.61 | +7.5% | Beat |
| 30 Jul 2025 16:00 | 0.44 | 0.48 | +8.3% | Beat |
| 01 May 2025 16:00 | 0.33 | 0.32 | -2.6% | Miss |
| 13 Feb 2025 16:00 | 0.50 | 0.45 | -9.9% | Miss |
| 24 Oct 2024 16:00 | 0.43 | 0.45 | +3.5% | Beat |
| 25 Jul 2024 16:00 | 0.39 | 0.43 | +11.4% | Beat |
| 25 Apr 2024 17:00 | 0.27 | 0.32 | +18.6% | Beat |
| 08 Feb 2024 16:00 | 0.43 | 0.50 | +16.0% | Beat |
| 26 Oct 2023 16:00 | 0.33 | 0.50 | +50.0% | Beat |
| 27 Jul 2023 16:00 | 0.23 | 0.34 | +50.6% | Beat |
| 27 Apr 2023 16:00 | 0.15 | 0.17 | +17.1% | Beat |
| 09 Feb 2023 16:00 | 0.28 | 0.34 | +23.1% | Beat |
| 27 Oct 2022 16:00 | 0.24 | 0.28 | +15.9% | Beat |
| 28 Jul 2022 16:00 | 0.19 | 0.17 | -10.2% | Miss |
| 28 Apr 2022 16:00 | 0.13 | 0.08 | -38.8% | Miss |
| 10 Feb 2022 16:00 | 0.21 | 0.17 | -19.9% | Miss |
| 28 Oct 2021 16:00 | 0.16 | 0.22 | +37.8% | Beat |
| 29 Jul 2021 16:00 | 0.11 | 0.19 | +71.1% | Beat |
| 29 Apr 2021 16:00 | 0.07 | 0.08 | +14.3% | Beat |
| 11 Feb 2021 16:00 | 0.23 | 0.23 | -1.6% | Miss |
| 27 Oct 2020 16:00 | 0.16 | 0.24 | +42.4% | Beat |
| 28 Jul 2020 16:00 | 0.09 | 0.20 | +118.9% | Beat |
| 28 Apr 2020 17:00 | 0.04 | 0.11 | +195.1% | Beat |
| 13 Feb 2020 16:00 | 0.18 | 0.29 | +57.3% | Beat |
| 06 Nov 2019 16:00 | 0.05 | 0.16 | +219.2% | Beat |
| 31 Jul 2019 16:00 | — | 0.02 | +977.2% | Beat |
| 01 May 2019 16:00 | -0.04 | -0.01 | +66.0% | Beat |
| 21 Feb 2019 16:00 | 0.04 | 0.14 | +239.1% | Beat |
| 06 Nov 2018 16:00 | -0.02 | 0.04 | +276.3% | Beat |
| 01 Aug 2018 16:00 | -0.04 | -0.02 | +43.3% | Beat |
| 02 May 2018 16:00 | -0.09 | -0.08 | +11.8% | Beat |
| 27 Feb 2018 16:00 | 0.01 | 0.03 | +232.5% | Beat |
| 01 Nov 2017 16:00 | -0.04 | -0.01 | +75.4% | Beat |
| 01 Aug 2017 16:00 | -0.06 | -0.04 | +27.6% | Beat |
| 02 May 2017 16:00 | -0.12 | -0.12 | -1.4% | Miss |
| 28 Feb 2017 16:00 | -0.03 | -0.02 | +15.0% | Beat |
| 01 Nov 2016 16:00 | -0.03 | -0.05 | -65.2% | Miss |
| 02 Aug 2016 16:00 | -0.03 | -0.06 | -108.7% | Miss |
| 27 Apr 2016 16:00 | -0.05 | -0.06 | -11.4% | Miss |
| 23 Feb 2016 16:00 | — | 0.01 | +410.6% | Beat |
| 04 Nov 2015 16:00 | — | -0.02 | -2,677.8% | Miss |
| 05 Aug 2015 23:00 | -0.01 | -0.01 | -98.4% | Miss |
| 29 Apr 2015 16:00 | -0.03 | -0.04 | -60.8% | Miss |
| 25 Feb 2015 16:00 | -0.01 | 0.01 | +169.7% | Beat |
| 06 Nov 2014 16:00 | -0.01 | -0.02 | -27.3% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 4.7B | +15.6% | 836.3M | 17.9% | 2.09 | +47.2% | 1.1B |
| 2024 | 4B | +11.3% | 576.2M | 14.3% | 1.42 | +9.2% | 630.7M |
| 2023 | 3.6B | +24.5% | 541.5M | 14.9% | 1.30 | +58.5% | 511.9M |
| 2022 | 2.9B | — | 341.2M | 11.7% | 0.82 | — | 304.7M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 82.94 | 90.25 | 78.93 | 82.06 | -0.28% | 37,132,703 | |
| Oct 2026 | 86.46 | 88.87 | 76.52 | 82.29 | -4.64% | 100,503,500 | |
| Sep 2026 | 90.83 | 92.34 | 82.29 | 86.29 | -5.24% | 84,632,700 | |
| Aug 2026 | 85.25 | 92.59 | 82.09 | 91.06 | +9.12% | 103,252,300 | |
| Jul 2026 | 68.16 | 84.70 | 67.87 | 83.45 | +23.90% | 105,221,100 | |
| Jun 2026 | 73.49 | 78.91 | 67.30 | 67.35 | -8.67% | 111,052,400 | |
| May 2026 | 60.99 | 73.83 | 57.66 | 73.74 | +23.83% | 148,564,300 | |
| Apr 2026 | 62.80 | 66.44 | 56.72 | 59.55 | -5.18% | 89,148,000 | |
| Mar 2026 | 72.37 | 73.91 | 61.62 | 62.80 | -14.48% | 90,182,000 | |
| Feb 2026 | 72.71 | 75.36 | 62.86 | 73.43 | +0.53% | 98,108,000 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Is DexCom Stock Cheaper Now That Its Multiple Has Fallen? (opens in a new tab) Trefis · 11 Nov 2026 21:17
- Dexcom Announces Upcoming Conference Presentation (opens in a new tab) 10 Nov 2026 14:00
- What Is Behind The Move In DexCom Stock? (opens in a new tab) Trefis · 07 Nov 2026 12:49
- He went from washing lab equipment for $10 an hour to leading a $30 billion healthcare company. His advice to Gen Z: Raise your hand (opens in a new tab) Fortune · 07 Nov 2026 09:00
- Guardant Health (GH) Could Be 17% Undervalued As Board Appointment Tests Valuation (opens in a new tab) Simply Wall St. · 05 Nov 2026 05:19
- Will Shield Award Recognition Change Guardant Health Stock Narrative (opens in a new tab) Simply Wall St. · 05 Nov 2026 04:41
- DexCom to Launch 15-Day G7 CGM System in Canada This November (opens in a new tab) Zacks · 03 Nov 2026 15:59
- Biosensors - Global Strategic Business Report: Secure Share of the $53.7 Billion Market by 2030 as Abbott, Dexcom, Medtronic and Masimo Accelerate Wearable and AI Diagnostics (opens in a new tab) 03 Nov 2026 14:41
- Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion (opens in a new tab) MedTech Dive · 02 Nov 2026 16:35
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign (opens in a new tab) 02 Nov 2026 13:00
- Dexcom lifts 2026 revenue outlook after positive Q3 (opens in a new tab) Medical Device Network · 02 Nov 2026 12:24
- DexCom, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 02 Nov 2026 03:39
- DexCom: Improving Patient Access Makes It A Long-Term Buy (opens in a new tab) SeekingAlpha · 01 Nov 2026 23:27
- DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory (opens in a new tab) StockStory · 01 Nov 2026 02:43
- DexCom (DXCM) Stock Looks Below Fair Value on Cash Flow (opens in a new tab) Simply Wall St. · 31 Oct 2026 10:13
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 81.39 USD
- Market cap
- 30.5B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Medical Devices
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 23.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 19.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 8.1 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 31.51× | Weak | 30.56× |
| P/E (forward) | 25.63× | Weak | 14.16× |
| Price / book | 11.82× | Weak | 3.5× |
| Price / sales | 5.87× | Weak | 3.33× |
| EV / EBITDA | 19.71× | Weak | 11.19× |
| Free cash flow yield | 2.7% | Fair | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 63.4% | Good | 54.9% |
| Operating margin | 24% | Good | 5.8% |
| Net margin | 19.4% | Good | 1.2% |
| Return on equity | 37.7% | Good | 4.4% |
| Return on assets | 11.1% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 17% | Good | 10.1% |
| EPS growth / year | 36.6% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.55× | Good | 0.4× |
| Net debt / EBITDA | -0.28× | Good | 1.46× |
| Interest cover | 49.83× | Good | 2.17× |
| Current ratio | 1.74× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow DXCM and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.